Skip to main content
. 2012 May 28;2:67. doi: 10.3389/fcimb.2012.00067

Table 3.

Serum susceptibility phenotypes of additional B. cenocepacia clinical isolates.

Isolate RAPD type % Growth at 12 h (±SEM) Serum resistance phenotype EPS
C0131 04 98.7 (2.3) R ++
C1257 01 26.4 (5.7) I +++
C2303 06 1.9 (2.0) S ++
C2457 06 3.53 (2.8) S +++
C3883 04 93.7 (3.3) R +++
C4526 04 70.7 (26.4) I +++
C5491 01 40.2 (16.0) I
C5819 04 177.3 (19.8) R ++
C6114 04 107.9 (42.0) R +++
C6144 06 0.7 (0.5) S
C6159 073a 89.4 (6.3) R ++
C6345 02 8.8 (4.9) S
C6483 02 99.4 (10.9) R
C6615 X 86.7 (5.6) R
C7586 04 149.5 (3.7) R +++d
C7755 067 90.5 (1.8) R +++d
C7788 04 104.3 (29.7) R
D0134 X 123.6 (17.3) R +++
D0960 06 99.3 (3.7) R +++d
D1817 04 159.0 (3.4) R +++
D2282 06 172.5 (1.5) R +++d

Serum resistance phenotypes were determined using the Bioscreen growth method. R, resistant (>80% growth in serum); S, sensitive (<20% growth in serum); and I, intermediate (20–80% growth in serum) at 12 h. RAPD types are strain types as determined previously by RAPD PCR and exopolysaccharide (EPS) phenotypes were previously determined by growth on yeast extract mannitol media (Mahenthiralingam et al., 1996; Zlosnik et al., 2008). Experiments were performed in triplicate on three separate days. X = RAPD type not assigned but does not match a major existing RAPD type.